EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Otsuka Holdings Co. Ltd (OTSKF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Otsuka Holdings Co. Ltd $85.00, price $73.16, upside +16.2%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US

OH Otsuka Holdings Co. Ltd logo Broad data Sep 28, 2026

Otsuka Holdings Co. Ltd

OTSKF · US

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value $85.00 · Undervalued (+16.2%)
✓Quality 67/100
✓Healthy Growth (revenue 5y +11.7 %/yr)
✓Solidly profitable · 15.0% net margin (TTM)
✓Low debt · generates free cash flow
✓1.4% dividend yield · Well covered
✓Ranks above peers (13/14)
!Moderate moat 61/100
!Weak on dividend: 28 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$77.53 $23.79 Fair Value $85.00 Jun 2015 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range $23.79 – $77.53 · fair‑value band $55.85 – $109.40 · the $73.16 price screens below the $85.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.

Follow Otsuka Holdings Co. in your weekly email

Every Wednesday you see whether Otsuka Holdings Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide.

Show more

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.

Stock analysis

Otsuka Holdings Co. Ltd (OTSKF) currently trades at $73.16, while our model-based Fair Value estimate is $85.00, implying the stock looks roughly 13.9% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $86.59 per share, and 16 of the 26 models we run sit above the $73.16 price.

Bear case: the Dividend Discount group reads lowest at $13.00, and 10 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $55.85 (bear) to $109.40 (bull), the price of $73.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Otsuka Holdings Co. Ltd reported revenue of ¥2.5T in FY2025 versus ¥1.5T in FY2021, a compound +13.3%/yr. Reported net income was ¥363B in FY2025, compounding +30.5%/yr from FY2021.

Key figures

Market cap $38.8B · P/E ratio 17.1 · P/S ratio 2.52 · EPS (TTM) $4.27 · Dividend yield 1.4% · Net margin 14.7% · Return on equity 12.9% · Return on assets (EBIT) 6.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 36% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 16%, OTSKF screens cheaper than that median.

Fair Value models

Bear $55.85 Fair Value $85.00 Bull $109.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $51.40 $77.07 $116.27 80
Growth DCF $52.19 $74.91 $107.48 78
Owner Earnings $61.77 $93.23 $141.26 76
All 26 models by family
DCF Models
FCF DCF $51.40 $77.07 $116.27 80
Owner Earnings $61.77 $93.23 $141.26 76
5Y Revenue Exit $49.53 $75.95 $109.58 72
5Y EBITDA Exit $60.22 $95.96 $137.62 75
5Y P/E Exit $63.31 $101.74 $142.09 70
10Y Revenue Exit $48.39 $72.69 $105.17 66
10Y EBITDA Exit $56.59 $86.59 $126.58 68
10Y P/E Exit $58.56 $90.60 $129.99 63
Earnings-Based
Graham-Dodd $29.76 $92.79 $123.42 65
Lynch FV $20.19 $28.85 $37.50 61
PEG = 1.0 $20.19 $28.85 $37.50 57
EPV $41.04 $46.99 $52.19 74
Dividend Discount
Gordon GGM $7.85 $16.33 $25.91 66
DDM Multi-Stage $7.85 $13.00 $17.14 66
Multiples
P/E Multiple $72.22 $96.30 $120.37 63
P/S Multiple $55.81 $74.41 $93.01 58
P/B Multiple $55.81 $74.41 $93.01 55
EV/EBIT $68.77 $89.90 $111.02 66
EV/EBITDA $72.29 $94.59 $116.89 67
EV/Revenue $50.62 $70.01 $89.40 54
Asset-Based
NCAV (Graham) $18.28 $24.50 $36.56 54
Growth DCF
Growth DCF $52.19 $74.91 $107.48 78
Rev-Margin DCF $49.53 $76.00 $106.43 73
Economic Profit
Residual Income $33.99 $39.82 $54.96 76
ROIC Compounder $42.17 $52.13 $64.65 72
Growth Earnings
Growth-Adj P/E $59.46 $84.95 $110.43 67

Open the full fair value analysis →

Notify me when OTSKF reaches fair value

Put OTSKF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 66 · Market factors (momentum, volatility) 70

Profitability 57
Margins and returns on capital today
Quality Growth 47
Are margins and returns improving?
Cashflow 58
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 61
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 68
Price trend over the last 3–12 months (market factor)
52W Momentum 95
Distance to the 52-week high (market factor)
Net Issuance 96
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
What shareholders gained per year (last 5 years), in JPY (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+21.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+20.2%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.9% vs 14.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 17%
2025 sits 178% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +4.2% a year for the price and +1.8% for the forecasts.
Forecast 2026 (sales)+11.0%
Forecast 2027 (sales)+2.3%
Projected 2028 (sales)+2.3%
Projected 2029 (sales)+2.3%
Projected 2030 (sales)+2.2%

Watch OTSKF, get fair value alerts →

Compare Otsuka Holdings Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 67 · Above median
Fair Value upside +27.7% · Top 25%
Profitability
Return on equity (TTM) 12.9% · Above median
Return on assets 7.5% · Above median
Net margin (TTM) 15.0% · Above median
Operating margin (TTM) 18.8% · Above median
Growth and dividend
Revenue growth 8.2% · Above median
Dividend yield (TTM) 1.4% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 17.1× · Cheaper than median
P/B 2.02× · Cheaper than median
P/S (TTM) 2.43× · Cheaper than median
P/FCF 19.4× · Cheaper than median
EV/EBITDA 9.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)70 · sector 19
FUTURE (revenue growth)41 · sector 33
PAST (return on equity)52 · sector 41
HEALTH (low debt)99 · sector 92
DIVIDEND (yield)28 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,157 $749.08 −35%
Johnson & Johnson, JNJ $264.74 $168.85 −36%
AbbVie Inc ABBV $261.59 $259.62 −1%
Roche Holding RO CHF 375.20 CHF 326.56 −13%
Merck & Co MRK $143.81 $129.26 −10%
Novartis AG NOVN CHF 118.06 CHF 121.90 +3%
Amgen Inc AMGN $421.51 $463.66 +10%
Gilead Sciences, Inc GILD $149.05 $198.77 +33%
Pfizer Inc PFE $28.12 $24.87 −12%
Bristol-Myers Squibb Company BMY $62.40 $75.96 +22%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Otsuka Holdings Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/OTSKF

Frequently asked questions

Is Otsuka Holdings Co. Ltd (OTSKF) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of $85.00 versus a price of $73.16, about +16% upside (undervalued).
What is the fair value of OTSKF?
Our model-based fair value for Otsuka Holdings Co. Ltd is $85.00 (as of Sep 28, 2026), built from audited fundamentals. The current price: $73.16.
What is the quality score of OTSKF?
Otsuka Holdings Co. Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Otsuka Holdings Co. Ltd (OTSKF)?
Our model-based price target is the fair value of $85.00 (as of Sep 28, 2026) from 26 valuation models. Cautious scenario $55.85, optimistic scenario $109.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Otsuka Holdings Co. Ltd stock forecast for 2026?
Our models put fair value at $85.00, about +16% upside versus a price of $73.16 (undervalued). Cautious scenario $55.85, optimistic scenario $109.40. The calculation is refreshed regularly with new filings.
What is the revenue of Otsuka Holdings Co. Ltd (OTSKF)?
Otsuka Holdings Co. Ltd reported trailing-twelve-month revenue of about ¥2.5T (latest available figure, as of Sep 28, 2026).
Does Otsuka Holdings Co. Ltd pay a dividend?
Otsuka Holdings Co. Ltd currently shows a dividend yield of about 1.42% relative to its recent price (as of Sep 28, 2026).
What growth is priced into Otsuka Holdings Co. Ltd (OTSKF)?
For today's price to be fair in a discounted-cash-flow model, Otsuka Holdings Co. Ltd would have to grow free cash flow by +6.3 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.7 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of OTSKF use?
Our models discount Otsuka Holdings Co. Ltd at 9.2 %: a base by market capitalisation (large), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Otsuka Holdings Co. Ltd that is +6.3 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Otsuka Holdings Co. Ltd (OTSKF) delivered so far?
Over the past 5 years revenue at Otsuka Holdings Co. Ltd grew +11.7 % a year. The price currently implies +6.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Otsuka Holdings Co. Ltd (OTSKF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Otsuka Holdings Co. Ltd (+6.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Otsuka Holdings Co. Ltd (OTSKF)?
The free-cash-flow yield on the price is 5.16 %: that much free cash flow Otsuka Holdings Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Otsuka Holdings Co. Ltd (OTSKF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Otsuka Holdings Co. Ltd it is $85.00 per share (as of Sep 28, 2026), against a price of $73.16. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Otsuka Holdings Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 28, 2026, OTSKF trades below its calculated fair value: price $73.16, fair value $85.00, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OTSKF?
No. The price is what the market pays today ($73.16); the fair value is what the company's own numbers justify ($85.00). For Otsuka Holdings Co. Ltd the two are $11.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Otsuka Holdings Co. Ltd worth?
The market values Otsuka Holdings Co. Ltd at about $38.8B (market capitalisation, as of Sep 28, 2026). Per share that is $73.16; our models calculate a fair value of $85.00 per share.
What do the bullish and bearish scenarios say about OTSKF?
Our models span a range for Otsuka Holdings Co. Ltd: cautious scenario $55.85, base $85.00, optimistic $109.40 per share (as of Sep 28, 2026, price $73.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OTSKF?
Otsuka Holdings Co. Ltd trades at a price-to-earnings ratio of 17.1 (as of Sep 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $85.00 is built from several models across several years. Other multiples: P/B 2.0, P/S 2.4, EV/EBITDA 9.5.
How solid is the balance sheet of Otsuka Holdings Co. Ltd (OTSKF)?
Balance-sheet figures for Otsuka Holdings Co. Ltd (as of Sep 28, 2026): return on equity 12.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is OTSKF from its 52-week high?
Otsuka Holdings Co. Ltd trades at $73.16, about 6% below its 52-week high of $77.53 and 36% above the low of $53.89 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $85.00 is for.
Which stocks are comparable to Otsuka Holdings Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Otsuka Holdings Co. Ltd stock attractive at the current price?
The data as of Sep 28, 2026: price $73.16, calculated fair value $85.00 (+16%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OTSKF calculated?
We run Otsuka Holdings Co. Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $85.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Otsuka Holdings Co. Ltd currently trades 14 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Otsuka Holdings Co. Ltd (OTSKF)?
The closing price on Oct 2, 2026 was $73.16. Our model-based fair value is $85.00, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Otsuka Holdings Co. Ltd right now?
A fairly wide model range ($55.85 to $109.40) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Otsuka Holdings Co. Ltd (OTSKF) come from?
Earnings per share at Otsuka Holdings Co. Ltd grew +10.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.5 %, EBIT margin +1.8 %, tax rate +2.7 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Otsuka Holdings Co. Ltd

How large is the market capitalisation of Otsuka Holdings Co. Ltd (OTSKF)?
The market capitalisation of Otsuka Holdings Co. Ltd is $38.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Otsuka Holdings Co. Ltd (OTSKF)?
The price-to-sales ratio of Otsuka Holdings Co. Ltd is 2.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Otsuka Holdings Co. Ltd (OTSKF)?
Earnings per share at Otsuka Holdings Co. Ltd are $4.27 (price ÷ EPS = P/E 17.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Otsuka Holdings Co. Ltd (OTSKF)?
The dividend yield of Otsuka Holdings Co. Ltd is 1.4% (payout 24.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Otsuka Holdings Co. Ltd (OTSKF)?
The net margin of Otsuka Holdings Co. Ltd is 14.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Otsuka Holdings Co. Ltd (OTSKF)?
The return on equity (ROE) of Otsuka Holdings Co. Ltd is 12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Otsuka Holdings Co. Ltd (OTSKF)?
On an EBIT basis the return on assets of Otsuka Holdings Co. Ltd is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Otsuka Holdings Co. Ltd (OTSKF)?
The operating margin of Otsuka Holdings Co. Ltd is 18.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Otsuka Holdings Co. Ltd (OTSKF)?
Revenue at Otsuka Holdings Co. Ltd is growing +8.2% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Otsuka Holdings Co. Ltd (OTSKF)?
Earnings per share at Otsuka Holdings Co. Ltd are growing +17.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Otsuka Holdings Co. Ltd (OTSKF) hold?
Otsuka Holdings Co. Ltd holds more cash than debt, ¥307B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Otsuka Holdings Co. Ltd in the live analysis

One click puts Otsuka Holdings Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.